European Authorities Approve Lyophilized S/D Treated Plasma OctaplasLG® for Pre-Hospital Transfusion
Octapharma AG today announced that European medical authorities have approved the lyophilised presentation of the well-established octaplasLG® - pharmaceutically-licensed S/D treated plasma for transfusion. The line extension, which will be marketed in Europe as a powder and solvent for solution for infusion, offers new and potentially life-saving treatment options in pre-hospital and emergency settings.
“The European authorization of octaplasLG® powder continues Octapharma's ongoing commitment to help prevent uncontrolled haemorrhage associated with trauma, which accounts for 30%-50% of all deaths in the first 24 hours"1-5, says Dr. Oliver Hegener, Vice President IBU Critical Care.
Trauma results in 4.4 million deaths worldwide annually6, with uncontrolled bleeding being the major cause of potentially preventable death. Trauma-induced coagulopathy (TIC) is an early abnormal response characterised by hypocoagulation, in addition to acute blood loss, shock, hypothermia and metabolic acidosis, that begins soon after injury. Early - pre-hospital - administration of plasma has been shown to increase survival, compared with crystalloids, when pre-hospital transport was longer than 20 minutes.7
Until now, access to early plasma transfusion was limited by logistic hurdles as well as a lack of available transfusion medicine in the pre-hospital setting for both for civilian and military patients.
"octaplasLG® powder, an AB universal plasma, can be stored at room temperature and reconstituted within minutes, representing a potentially lifesaving treatment option in emergency situations and in locations with limited frozen storage facilities and cold chain infrastructure required for regular FFP," explains Dr. Hegener.
Pharmaceutical grade human plasma for infusion with standardised quality and unique pathogen safety profiles due to Octapharma’s integrated pathogen elimination/inactivation concept. The standardised content is achieved by pooling between 630 and 1520 single plasma units from multiple carefully screened donors. Safety measures present during manufacturing include: Donor screening, immunoneutralisation, Solvent/detergent treatment and Ligand affinity chromatography for prion reduction.
The product is approved for:
- Complex deficiencies of coagulation factors such as coagulopathy due to severe hepatic failure or massive transfusion.
- Substitution therapy in coagulation factor deficiencies, when a specific coagulation factor concentrate (e.g., factor V or factor XI) is not available for use or in emergency situations when a precise laboratory diagnosis is not possible.
- Rapid reversal of the effects of oral anticoagulants (coumarin or indanedione type) when a prothrombin complex concentrate is not available for use or administration of vitamin K is insufficient due to impaired liver function or in emergency situations.
- Potentially dangerous haemorrhages during fibrinolytic therapy, using e.g., tissue plasminogen activators, in patients who fail to respond to conventional measures.
- Therapeutic plasma exchange procedures, including those in thrombotic thrombocytopenic purpura (TTP).
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.
Octapharma employs more than 11,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology, and Critical Care.
Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 190 plasma donation centres across Europe and the US.
1. Bosch F, Angele MK, Chaudry IH. Gender differences in trauma, shock and sepsis. Mil Med Res. 2018;5(1):35.
2. Iapichino GE, Ponschab M, Cadamuro J, et al. Concentrated lyophilized plasma used for reconstitution of whole blood leads to higher coagulation factor activity, but unchanged thrombin potential compared with fresh-frozen plasma. Transfusion. 2017;57(7):1763-71.
3. Nguyen C, Bordes J, Cungi PJ, et al. Use of French lyophilized plasma transfusion in severe trauma patients is associated with an early plasma transfusion and early transfusion ratio improvement. J Trauma Acute Care Surg. 2018;84(5):780-5.
4. Moore EE, Moore HB, Kornblith LZ, et al. Trauma-induced coagulopathy. Nat Rev Dis Primers. 2021;7(1):30.
5. Johansson PI, Sorensen AM, Perner A, et al. Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study. Crit Care. 2011;15(6): R272.
6. World Health Organization. Injuries and violence. 19 March 2021. Available at: https://www.who.int/news-room/fact-sheets/detail/injuries-and-violence. Last accessed January 2023.
7. Pusateri AE, Moore EE, Moore HB, et al. Association of Prehospital Plasma Transfusion With Survival in Trauma Patients With Hemorrhagic Shock When Transport Times Are Longer Than 20 Minutes: A Post Hoc Analysis of the PAMPer and COMBAT Clinical Trials. JAMA Surg. 2020;155(2): e195085.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005552/en/
Ivana Spotakova, Communications Manager
email@example.com, Tel.: +41793474607
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dealroom and RockawayX Publish 2023 Report on the State of European Crypto Company Funding22.3.2023 17:00:00 EET | Press release
Today, RockawayX (a venture capital firm backing leading Web3 projects) and Dealroom published its State of European Crypto Funding report. Published in full here, the highlights of the report include: Unicorn creation across all geographies peaked in 2021. European crypto startups attracted record funding ($5.7BN) in 2022, while US crypto startup funding declined YoY. Europe has the largest number of crypto startups but lags in late-stage companies. European startups account for a substantial portion of early-stage crypto funding globally. US investors’ share of European crypto startup Seed and Series A funding was 21% and 29%. London remains the crypto hub of Europe. “Web3” is rising, with users mounting, big brand entrants, and increased venture funding. More than half of European crypto VC funding goes to companies building financial products and services. Funding in companies building developer tools, roll-ups, and “Layer 1s” accelerated the most in 2022. “The crypto market has be
Rimini Street Formally Launches Rimini ONE™, an End-to-End Outsourcing Solution for Enterprise Applications, Databases and Technology Software22.3.2023 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced the formal launch of Rimini ONE™, its outsourcing service program designed to offer a comprehensive set of unified, integrated services to run, manage, support, customize, configure, connect, protect, monitor, and optimize enterprise applications, databases and technology software. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230322005298/en/ Rimini ONE’s comprehensive, trusted, and proven family of unified solutions optimize, evolve, and transform clients’ enterprise software and organization to support competitive advantage, profitability, and growth. (Graphic: Business Wire) “We developed Rimini ONE in response to clients requesting a fully outsourced solution for their enterprise sof
AGCO Agriculture Foundation Awards $50,000 Grant to Providence Farm Collective22.3.2023 16:00:00 EET | Press release
The AGCO Agriculture Foundation (AAF), a private foundation with the vision to prevent and relieve hunger through sustainable agricultural development, today announced a USD 50,000 grant to Providence Farm Collective (PFC) to support implementation of a holistic on-farm compost generation system and optimization of post-harvest efficiency and food safety at its 37-acre farm in Orchard Park, NY. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230322005050/en/ AGCO Agriculture Foundation Awards $50,000 Grant to Providence Farm Collective. Funds will support refugee and under-resourced communities to grow food and improve food handling and safety practices. (Graphic: Business Wire) PFC is a non-profit that supports refugee, immigrant, Black and low-income farmers in Western New York who cannot otherwise access farmland. The organization started in 2017 as a grassroots effort by the Somali Bantu community to return to their agric
Luno Announces Leadership Transition22.3.2023 13:00:00 EET | Press release
Luno, a leading cryptocurrency wallet and exchange serving customers across 40 countries, today announced a series of strategic initiatives to position the company for its next phase of growth. Luno’s co-founder and Chief Executive Officer Marcus Swanepoel is moving into a new role as Executive Chairman, and Chief Operating Officer James Lanigan, who has been with the company for five years, is elevated to CEO. As Executive Chairman, Swanepoel will continue to work closely with Lanigan to guide Luno’s vision and strategy, while focusing on broadening Luno’s investor base to support the company’s next stage of growth. As part of this process, Luno has hired Canaccord Genuity Group to help bring on new institutional and strategic investors alongside Digital Currency Group (DCG) to fund scaling, support expansion, accelerate market share gain, and prepare the company for an eventual public listing. “Co-founding and serving as the CEO of Luno for the past ten years has been the greatest ho
The LYCRA Company Announces Latest Higg Achievements22.3.2023 12:00:00 EET | Press release
The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel and personal care industries, announced today that several of its manufacturing sites had their Higg Facility Environmental Module (Higg FEM) and Higg Facility Social & Labor Module (Higg FSLM) self-assessments verified by an independent third party last year and achieved scores in the top quartile. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230322005015/en/ The LYCRA Company’s manufacturing sites in Waynesboro, Virginia; Maydown, Northern Ireland; and Foshan, China, completed verification for the Higg FEM module, while its Tuas, Singapore, and Maydown sites completed verification for the Higg FSLM module. The LYCRA Company’s manufacturing sites in Waynesboro, Virginia; Maydown, Northern Ireland; and Foshan, China, completed verification for the Higg FEM module, while its Tuas, Singapore, and Maydown sites completed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom